论文部分内容阅读
目的:观察布地奈德福莫特罗(信必可都保)治疗儿童中度哮喘的临床疗效。方法:50例中度哮喘患儿随机分为观察组和对照组,分别应用布地奈德福莫特罗和布地奈德气雾剂治疗10个月,观察两组患儿哮喘急性发作次数及治疗前后肺功能(FEV1和PEF预计值%)的变化。结果:观察组哮喘急性发作次数明显少于对照组;2组均可提高FEV1和PEF预计值%,改善肺功能,但治疗组明显优于对照组。结论:布地奈德福莫特罗治疗儿童哮喘的临床疗效较好,可以作为儿童哮喘的首选治疗。
Objective: To observe the clinical efficacy of budesonide formoterol (SINBEC) in the treatment of children with moderate asthma. Methods: Fifty children with moderate asthma were randomly divided into observation group and control group. The patients were treated with budesonide formoterol and budesonide aerosol respectively for 10 months. The number and treatment of acute asthma in both groups were observed Changes in lung function (FEV1 and predicted PEF%) before and after treatment. Results: The number of acute exacerbations in the observation group was significantly less than that in the control group. Both the FEV1 and PEF predictive values were improved and lung function was improved in both groups, but the treatment group was significantly better than the control group. Conclusion: The efficacy of budesonide formoterol in treating childhood asthma is better and can be the first choice of treatment for childhood asthma.